Why the study?
Although sST2 can be used to predict long-term prognosis after acute myocardial infarction, its prognostic role in AMI remains unclear.
Does elevated sST2 predict long-term all-cause mortality and MACEs in patients with acute myocardial infarction?
Does elevated sST2 predict long-term all-cause mortality and MACEs in patients with acute myocardial infarction?
Elevated sST2 is a significant predictor of long-term all-cause mortality and MACEs in patients with acute myocardial infarction.
The soluble suppression of tumorigenicity 2 (sST2) can be used to predict the long-term prognosis of acute myocardial infarction (AMI). However, the prognostic role of sST2 in AMI is unclear. This meta-analysis aimed to evaluate the association between sST2 and long-term clinical outcomes of AMI patients. Relevant literature was retrieved from PubMed, Embase, the Cochrane Library, and Web of Science databases. Meta-analysis was performed using hazard ratio (HR) and 95% confidence intervals (CIs) as effect measures. Thirteen studies with 11571 patients were finally included in the meta-analysis. Elevated sST2 predicted a poor outcome for all-cause mortality with a combined HR of 2.40 (95% CI: 1.64–3.51, P < 0.001) and major adverse cardiac events (MACEs) with the combined HR of 2.57 (95% CI: 1.56–4.24, P < 0.001). Subgroup analysis revealed that elevated sST2 was positively correlated with all-cause mortality and MACEs in the STEMI, NSTEMI, and unselected AMI subgroups. These results suggest that elevated sST2 can predict long-term prognosis for AMI patients.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: